The competition watchdog has urged the European Commission not to approve the proposed £10.3bn merger between O2 and Three.
CK Hutchison Holdings, the conglomerate which owns Three, announced it was looking to buy O2 from its Spanish parent Telefonica in March last year.
It would create the largest mobile operator in the UK, cornering more than a third of the market.
However, the deal is being investigated by European regulators amid concerns it could reduce competition and push up prices.
The UK’s Competition and Markets Authority (CMA) today wrote to EU competition commissioner Margrethe Vestager explaining why it objects to the merger.
CMA chief executive Alex Chisholm said: “We believe this merger would give rise to a significant impediment to effective competition in retail and wholesale mobile telecoms markets.”
He said measures offered by CK Hutchison to appease concerns “are materially deficient as they will not lead to the creation of a fourth Mobile Network Operator (MNO) capable of competing effectively and in the long-term with the remaining three MNOs such that it would stem the loss of competition caused by the merger”.
The only remedy the CMA would accept is the sale of either the Three or O2 business, to ensure there are still four competing mobile operators in the UK.
Full content: Telegraph
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas